Peter Forsyth, M.D.
Contact Information:
Room 2AA-07, Health Research Innovation Centre
3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1
Phone: 403-210-3934
Fax: 403-210-8135
Email: pforsyth@ucalgary.ca
Forsyth Lab Website
Dr. Peter Forsyth is a Professor in the Departments of Oncology, Clinical Neurosciences, and Biochemistry & Molecular Biology at the University of Calgary, the Associate Director Research at the Tom Baker Cancer Centre, and the Director of the Southern Alberta Cancer Research Institute.
He obtained his M.D. from McMaster University and then completed an internship in Medicine at the University of Toronto, and residency training in Neurology at the Mayo Clinic and Neuro-oncology at Memorial Sloan Kettering Cancer Center. He is a founding member of the Canadian Brain Tumor Group Executive, the Alberta Brain Tumor Group, the Oligodendroglioma Research Group and the Canadian Oncolytic Virus Consortium. He was the Brain Tumor Group Leader at the Tom Baker Cancer Centre from 1996-2006, the inaugural head of the Alberta Brain Tumor Group from 1996-2006, and the Inaugural Director of the Clark H. Smith Brain Tumor Center. Dr. Forsyth participates on numerous committees and has received many awards of distinction including a Golden Apple Award for Teaching, an Award of Excellence in Medicine & Health, the Eldon Smith Award for Academic Excellence, and Faculty of Medicine Award for Research.
Dr Forsyth's research focuses on the molecular genetics of malignant gliomas, mechanisms of glioma invasion, and the treatment of malignant gliomas with viral therapies. He is interested in improving the treatment and care of patients with malignant brain tumors through "translational" research. As a clinician, Dr Forsyth is developing new approaches to treatment that could offer real hope to patients.
Selected Publications:
Coffey M, Strong J, Forsyth P, Lee P. Reovirus therapy of tumor with activated ras pathways Science, 282: 1332-1334,1998.
Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PMA, Shi ZQ, Johnston RN, Nishikawa S, Lee PWK, Forsyth PA. Reovirus as an oncolytic agent against experimental human malignant gliomas. Journal of the National Cancer Institute. 93:903-912, 2001.
Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A, Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. Journal of Clinical Oncology. 22:1583-1588, 2004.
Parato K, Senger D, Forsyth PA, Bell J. Recent progress in the battle between oncolytic viruses and tumours. Nature Reviews Cancer. 5:965-976, 2005
Lun XQ*, Yang WQ*, Alain T, Shi ZS, Muzik HM, Barrett JW, McFadden G, Bell J, Hamilton MG, Senger DL, PA Forsyth. Myxoma virus is a novel oncolytic virus with significant anti-tumor activity against experimental human gliomas. Cancer Research 65 9982-9990, 2005.
Lun XQ, Senger DL, Alain T , Parato K, Stojdl D, Lichty B, Johnston RN, Hamilton MG, Parney I, Bell JC, Forsyth PA. Recombinant Vesicular Stomatitis Virus (VSV∆M51) prolongs survival and targets multi-focal and invasive gliomas when administered intravenously. Journal of the National Cancer Institute 98: 1546-57, 2006.
Alain T, Kim T, Liacini H, Senger D, Forsyth PA. Proteolytic disassembly is a critical determinant of reovirus oncolysis. Molecular Therapy 8: 1512-21, 2007.
Johnston ALM, Lun XQ, Hempstead BL, Robbins, SM, Forsyth PA* & Senger DL* The Neurotrophin Receptor p75 Mediates Glioma Invasion. PLoS Biology 5: 0001-0015, 2007 (*senior authorship shared; PF is corresponding author).
Brown, R., Zlatescu, M., Sijben, S., Roldan, G., Easaw, J., Forsyth, P., Parney, I., Sevick, R., Yan, E., Demetrick, D., Schiff, D., Cairncross, J. & Mitchell, J. Detecting Genetic Signatures in Oligodendroglioma Non-Invasively Using MR, Clinical Cancer Research (in press).
